ENDRA Life Sciences (NDRA) Net Equity Issued and Repurchased (2016 - 2026)
ENDRA Life Sciences (NDRA) posted quarterly Net Equity Issued and Repurchased of $263747.0 for Q1 2026, up 80.89% year-over-year from $145803.0 in Q1 2025, and up 302.3% quarter-over-quarter from $65559.0 in Q4 2025.
ENDRA Life Sciences (NDRA) Net Equity Issued and Repurchased (2016 - 2026) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Net Equity Issued and Repurchased for 11 consecutive years, with $263747.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased rose 80.89% year-over-year to $263747.0; the TTM figure through Mar 2026 stood at $1.3 million (down 73.77% YoY), while the FY2025 annual figure was $1.2 million, down 77.31% from the prior year.
- Net Equity Issued and Repurchased rose to $263747.0 in Q1 2026 per NDRA's latest filing, from $65559.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $7.5 million in Q2 2022 and bottomed at $65559.0 in Q4 2025.
- Historically, Net Equity Issued and Repurchased has averaged $1.7 million across 5 years, with a median of $728503.0 in 2024.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 542.48% — and 2025, when it slumped 98.45%.
- ENDRA Life Sciences' Net Equity Issued and Repurchased stood at $7.5 million in 2022, then sank by 91.3% to $656811.0 in 2023, then surged by 542.48% to $4.2 million in 2024, then plunged by 98.45% to $65559.0 in 2025, then surged by 302.3% to $263747.0 in 2026.
- Business Quant data shows NDRA's Net Equity Issued and Repurchased at $263747.0 in Q1 2026, $65559.0 in Q4 2025, and $149466.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.40 Bn | 209.33 Bn | 8.34 Bn | - |
| 2 | Danaher | 139.94 Bn | 135.59 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.03 Bn | 45.83 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.69 Bn | 37.88 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.32 Bn | 37.24 Bn | 1.44 Bn | - |
| 6 | Natera | 38.47 Bn | 37.37 Bn | 696.04 Mn | - |
| 7 | Illumina | 29.98 Bn | 28.82 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.57 Bn | 28.52 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.21 Bn | 25.58 Bn | 1.03 Bn | - |
| 10 | ENDRA Life Sciences | 5.44 Mn | 5.08 Mn | - | 263,747.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 263,747.00 |
| Mar 31, 2026 | 263,747.00 |
| Dec 31, 2025 | 65,559.00 |
| Dec 31, 2025 | 65,559.00 |
| Sep 30, 2025 | 149,466.00 |
| Sep 30, 2025 | 149,466.00 |
| Jun 30, 2025 | 857,415.00 |
| Jun 30, 2025 | 857,415.00 |
| Mar 31, 2025 | 145,803.00 |
| Mar 31, 2025 | 145,803.00 |
| Dec 31, 2024 | 4.22 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Jun 30, 2024 | 728,503.00 |
| Jun 30, 2024 | 728,503.00 |
| Mar 31, 2024 | 419,967.00 |
| Mar 31, 2024 | 419,967.00 |
| Dec 31, 2023 | 656,811.00 |
| Dec 31, 2023 | 656,811.00 |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |